BioLineRx (NASDAQ:BLRX) Upgraded by to Hold upgraded shares of BioLineRx (NASDAQ:BLRXFree Report) from a sell rating to a hold rating in a research note issued to investors on Monday.

Separately, HC Wainwright reissued a buy rating and set a $21.00 price objective on shares of BioLineRx in a report on Wednesday, May 29th.

Read Our Latest Stock Report on BLRX

BioLineRx Trading Down 1.6 %

NASDAQ BLRX opened at $0.73 on Monday. The company has a quick ratio of 1.05, a current ratio of 1.14 and a debt-to-equity ratio of 0.45. BioLineRx has a 52 week low of $0.55 and a 52 week high of $2.53. The business has a 50 day moving average price of $0.72 and a 200-day moving average price of $1.15. The company has a market cap of $58.68 million, a price-to-earnings ratio of -0.97 and a beta of 1.54.

BioLineRx (NASDAQ:BLRXGet Free Report) last posted its quarterly earnings results on Tuesday, May 28th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.28. The business had revenue of $6.86 million during the quarter, compared to analyst estimates of $0.34 million. During the same period in the previous year, the business posted ($0.15) EPS. As a group, equities analysts expect that BioLineRx will post -0.47 earnings per share for the current fiscal year.

Institutional Trading of BioLineRx

Institutional investors and hedge funds have recently made changes to their positions in the company. B. Riley Wealth Advisors Inc. increased its stake in BioLineRx by 88.5% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 21,300 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 10,000 shares during the last quarter. NorthRock Partners LLC bought a new position in BioLineRx in the 4th quarter valued at $27,000. Allen Mooney & Barnes Investment Advisors LLC purchased a new stake in shares of BioLineRx during the 3rd quarter valued at $46,000. Rathbones Group PLC bought a new stake in shares of BioLineRx during the 3rd quarter worth $72,000. Finally, PVG Asset Management Corp purchased a new position in shares of BioLineRx in the 4th quarter worth about $97,000. Hedge funds and other institutional investors own 1.56% of the company’s stock.

About BioLineRx

(Get Free Report)

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.

Recommended Stories

Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with's FREE daily email newsletter.